HEALTH● LOWJul 8 · Jul 8, 2026, 2:56 PM
Arcutis gets FDA review for Zoryve 0.05% label expansion
Seeking Alpha Tech
Arcutis has received FDA review for the label expansion of its drug, Zoryve 0.05%, which could lead to broader applications for the medication.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH19m agoLagos begins mandatory health insurance enforcement January 2027Vanguard NigeriaHEALTH56m agoBreast cancer prevention starts with knowing your riskThe HillHEALTH57m agoMedical experts warn climate change is now a 'global health emergency'RFI [en]HEALTH1h agoCurrent, former CMS leaders offer advice on Medicare changes aheadThe Hill